Clinical gene therapy restores hearing: a paradigm shift.

Area of Science:

• Otolaryngology
• Genetics
• Regenerative Medicine

Background:

• Autosomal recessive deafness 9 (DFNB9) results from OTOF gene mutations, a significant cause of hereditary hearing loss (HHL).
• Recent gene therapy advancements offer potential cures for previously untreatable forms of deafness.
• The OTOF gene plays a crucial role in auditory hair cell function.

Purpose of the Study:

• To review the progress of clinical trials for OTOF gene therapy in treating DFNB9.
• To highlight key translational aspects including drug delivery, trial design, and safety.
• To examine challenges and future directions for optimizing gene therapy in auditory medicine.

Main Methods:

• Systematic review of registered clinical trials for OTOF-related DFNB9.
• Analysis of translational foci: inner ear drug delivery, trial design, safety, and auditory outcomes.
• Critical examination of challenges: anatomical constraints, patient selection, and outcome standardization.

Main Results:

• Eight clinical trials for DFNB9 are underway across eight countries, indicating rapid development.
• Pioneering studies are establishing frameworks for gene therapy translation in auditory medicine.
• Progress is noted in inner ear drug delivery, trial design, safety, and auditory restoration.

Conclusions:

• Gene therapy for OTOF mutations represents a paradigm shift in treating hereditary hearing loss.
• Addressing anatomical, patient selection, and outcome measure challenges is crucial for future therapeutic optimization.
• Continued research and standardized approaches will accelerate the clinical translation of gene therapy for deafness.